Research Article
Evaluation of Monocarboxylate Transporter 4 in Inflammatory Bowel Disease and Its Potential Use as a Diagnostic Marker
Table 1
The characteristic of the inflammatory bowel disease patients.
| | Variables | Number of patients (%) | Lactic acid level (%) |
| | | | Increased | Normal | | Total | 54 | 43 (79.6) | 11 (20.4) | | Age | | | | | <10 years | 32 (59.3) | 26 (48.2) | 6 (11.1) | | ≥10 years | 22 (40.7) | 17 (31.4) | 5 (9.3) | | Gender | | | | | Male | 39 (72.2) | 30 (55.5) | 9 (16.7) | | Female | 15 (27.8) | 13 (24.1) | 2 (3.7) | | Type of IBD | | | | | Crohn’s disease | 40 (74.1) | 33 (61.1) | 7 (13.0) | | Ulcerative colitis | 14 (25.9) | 10 (18.5) | 4 (7.4) | | Stage | | | | | Active stage | 37 (68.5) | 30 (55.5) | 7 (13.0) | | Remission stage | 17 (31.5) | 13 (24.1) | 4 (7.4) | | Degree of mucosal inflammation | | | | | Mild | 17 (31.5) | 13 (24.1) | 4 (7.4) | | Moderate | 24 (44.4) | 19 (35.1) | 5 (9.3) | | Severe | 13 (24.1) | 11 (20.4) | 2 (3.7) | | Therapy | | | | | Hormone | 26 (48.2) | 23 (42.6) | 3 (5.6) | | Immunosuppressant | 8 (14.8) | 6 (11.1) | 2 (3.7) | | Hormone + immunosuppressant | 20 (37.0) | 14 (25.9) | 6 (11.1) |
|
|
|
